Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control - the MUSCA study

Next Previous
Search
Trial Profile

A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers of asthma control - the MUSCA study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma; Eosinophilia
  • Focus Registrational; Therapeutic Use
  • Acronyms MUSCA
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 01 Mar 2021 Results of post hoc meta analysis of data from the Phase III MENSA and MUSCA studies presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 16 Mar 2020 Results of a post hoc analysis of data from DREAM, MENSA and MUSCA Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 16 Mar 2020 Results (n=1189) of post-hoc pooled analysis of four studies ( DREAM, MENSA, SIRIUS, and MUSCA ) assessing impact of mepolizumab on clinically significant exacerbations and health-related quality of life (HRQoL) in patients with severe eosinophilic asthma and upper respiratory comorbidities, published at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top